A 24-year nationwide US analysis finds that pregnant women co-infected with hepatitis B and hepatitis delta face ...

Hepatitis delta virus (HDV), a bloodborne infection that is transmitted through infected blood or other bodily fluids, was recently designated as a Group 1 carcinogen by the International Agency for ...

Accurate detection and quantification of hepatitis delta virus (HDV) RNA are essential for diagnosis, prognosis and treatment monitoring. This study aimed to evaluate whether thermal shock ...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced the primary endpoint was met in the Phase 3 portion of the AZURE-1 study evaluating brelovitug, an ...

Gilead Sciences, Inc. announced that it will present new clinical and real-world evidence across primary biliary cholangitis (PBC) and chronic hepatitis delta virus (HDV) infection at The Liver ...

THURSDAY, June 4, 2026 (HealthDay News) -- The U.S. Food and Drug Administration has approved Hepcludex (bulevirtide-gmod) injection to treat chronic hepatitis delta virus (HDV) infection in adults ...

Findings showed 100% of participants taking the tobevibart and elebsiran combination achieved an undetectable HDV RNA at week 24 that was sustained through week 60. The Food and Drug Administration ...

CEO Marianne De Backer emphasized Vir's progress in advancing its infectious disease and oncology programs. Key milestones include initiating the ECLIPSE Phase III registrational program for hepatitis ...

Elebsiran and tobevibart are investigational agents being evaluated as a novel combination regimen administered monthly as two separate sequential subcutaneous injections for the treatment of chronic ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that tobevibart and elebsiran have received U.S. Food and Drug Administration (FDA) Breakthrough Therapy ...

EIT Pharma, Inc. ("EIT Pharma" or the "Company"), a biotechnology company focused on developing therapies for infectious ...